Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis

被引:58
作者
Friehs, I
Margossian, RE
Moran, AM
Hung, CD
Moses, MA
del Nido, PJ
机构
[1] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Cardiac Surg, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Childrens Hosp Boston, Vasc Biol Program, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Dept Pediat Cardiol, Boston, MA 02115 USA
关键词
hypertrophy; angiogenesis; matrix metalloproteinases;
D O I
10.1007/s00395-005-0581-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Pressure-overload hypertrophy is associated with decreased capillary density in myocardium resulting in impaired substrate delivery. Treatment of hypertrophied hearts with vascular endothelial growth factor (VEGF) induces angiogenesis. Since angiogenesis is associated with extracellular matrix degradation, we sought to determine whether VEGF induced angiogenesis in hypertrophy required matrix metalloproteinases (MMP) activation. Methods Newborn rabbits underwent aortic banding. Progression of hypertrophy (mass-to-volume (M/V) ratio) and mid-wall contractility index was monitored by echocardiography. At 4 and 6 weeks, VEGF (2 mu g/kg), vehicle or VEGF combined with GM6001 (5 mg/kg), a MMP inhibitor, was administered intrapericardially. CD-31 (indicator of angiogenesis), MMP-2, MT1-MMP and TIMPs (endogenous MMP inhibitors) expression were measured by immunoblotting. MMP-2 activity was determined by gelatin zymography. Results Untreated hypertrophied hearts progressed to ventricular dilatation at 7 wks (M/V ratio: 0.75 +/- 0.07), but compensatory hypertrophy was maintained with VEGF (0.91 +/- 0.07; p < 0.05). LV contractility declined in untreated hearts from -0.41 +/- 0.9 (5 wks) to -0.73 +/- 0.5 (7 wks; p < 0.05) but remained normal with VEGF (+1.61 +/- 0.6 vs. +0.47 +/- 0.2). MMP-2 expression and activity were significantly elevated in VEGF treated hypertrophied hearts (p < 0.05) and were blocked by concomitant administration of GM6001. VEGF induced neovascularization was inhibited by addition of GM6001. MT1-MMP showed a trend to higher levels in VEGF treated hearts. TIMPs were unchanged in all three groups. Conclusions Exogenous VEGF and resultant MMP-2 activation leads to increased capillary formation in severe hypertrophy, preventing progression to ventricular dilation and dysfunction. VEGF and the associated MMP-2 activation play an important and potentially therapeutic role in vascular remodeling of hypertrophied hearts.
引用
收藏
页码:204 / 213
页数:10
相关论文
共 36 条
[1]   ANGIOGENIC-INDUCED ENHANCEMENT OF COLLATERAL BLOOD-FLOW TO ISCHEMIC MYOCARDIUM BY VASCULAR ENDOTHELIAL GROWTH-FACTOR IN DOGS [J].
BANAI, S ;
JAKLITSCH, MT ;
SHOU, M ;
LAZAROUS, DF ;
SCHEINOWITZ, M ;
BIRO, S ;
EPSTEIN, SE ;
UNGER, EF .
CIRCULATION, 1994, 89 (05) :2183-2189
[2]  
BRAUNHUT SJ, 1994, J BIOL CHEM, V269, P13472
[3]   Timeline - Matrix metalloproteinases: a tail of a frog that became a prince [J].
Brinckerhoff, CE ;
Matrisian, LM .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (03) :207-214
[4]   Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations [J].
Coker, ML ;
Doscher, MA ;
Thomas, CV ;
Galis, ZS ;
Spinale, FG .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1999, 277 (02) :H777-H787
[5]  
Etoh T, 2001, CANCER RES, V61, P2145
[6]   Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model [J].
Fang, JM ;
Shing, Y ;
Wiederschain, D ;
Yan, L ;
Butterfield, C ;
Jackson, G ;
Harper, J ;
Tamvakopoulos, G ;
Moses, MA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (08) :3884-3889
[7]  
FRIDMAN R, 1992, J BIOL CHEM, V267, P15398
[8]  
Friehs I, 1999, CIRCULATION, V100, P187
[9]   Promoting angiogenesis protects severely hypertrophied hearts from ischemic injury [J].
Friehs, I ;
Moran, AM ;
Stamm, C ;
Choi, YH ;
Cowan, DB ;
McGowan, FX ;
del Nido, PJ .
ANNALS OF THORACIC SURGERY, 2004, 77 (06) :2004-2011
[10]   Insulin-like growth factor-1 improves postischemic recovery in hypertrophied hearts [J].
Friehs, I ;
Stamm, C ;
Cao-Danh, H ;
McGowan, FX ;
del Nido, PJ .
ANNALS OF THORACIC SURGERY, 2001, 72 (05) :1650-1656